Targeting homologous recombination deficiency in uterine leiomyosarcoma
Open Access
- 4 May 2023
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-20
Abstract
Background: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting. Methods: A cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting. Results: All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs. Conclusions: Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.Keywords
Funding Information
- Australian and New Zealand Gynaecological Oncology Group (ACF-07544)
- National Health and Medical Research Council (1062702)
- Stafford Fox Medical Research Foundation
- Cancer Council Victoria (1186314)
- Victorian Cancer Agency (CRF10-20, CRF16014)
This publication has 85 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsClinical Cancer Research, 2012
- A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEffFly, 2012
- dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictionsHuman Mutation, 2011
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancerNature Reviews Clinical Oncology, 2011
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cellsProceedings of the National Academy of Sciences, 2011
- A DNA-PKcs mutation in a radiosensitive T–B– SCID patient inhibits Artemis activation and nonhomologous end-joiningJournal of Clinical Investigation, 2008
- BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1tumour phenotypeBreast Cancer Research, 2008
- Prognostic factors and survival in 1396 patients with uterine leiomyosarcomasCancer, 2008
- Cisplatin as Second-Line Chemotherapy in the Treatment of Advanced or Recurrent Leiomyosarcoma of the Uterus A Phase II Trial of the Gynecologic Oncology GroupAmerican Journal of Clinical Oncology, 1986